One of the underappreciated stories of the GLP-1 class is that the cardiovascular benefits have kept showing up even in people who lose modest amounts of weight. The question always gets asked in the community: is the heart protection just a downstream effect of the weight loss, or is there something more direct going on? A study published in the BMJ earlier this month adds a strong data point, and it extends the picture to something you don’t hear about as often - severe infections.
The paper, reported by Harvard Health, looked at tirzepatide (Mounjaro, Zepbound) against an older diabetes drug, sitagliptin (Januvia). It’s worth going through the numbers carefully, because they’re the sort that deserve honest framing rather than hype.
What the study actually did
This was a claims-based observational study, not a randomised controlled trial. That distinction matters, and I’ll come back to it.
The analysis drew on US health insurance claims data from May 2022 to May 2025, covering nearly 53,000 people aged 40 and over. Everyone in the study had three things in common: excess weight (a BMI of 25 or higher), type 2 diabetes, and existing heart disease. About 35,000 were taking tirzepatide and the rest were taking sitagliptin, which is an older DPP-4 inhibitor rather than a GLP-1.
So this isn’t a study of healthy people on a weight-loss drug - it’s a study of a fairly sick, high-risk group, which is exactly where you’d expect to see cardiovascular differences if they exist.
The headline numbers
After one year, the risk of heart attack, stroke or death was 4.4% in the sitagliptin group versus 2.9% in the tirzepatide group. That’s a reduction of nearly a third - and the authors calculated that for every 70 patients starting tirzepatide, one case of heart attack, stroke or death would be prevented.
The infection finding is what makes this paper a little unusual. The tirzepatide group also had a lower risk of severe bacterial infections. Their need for hospitalisation from infections was cut by about a third, and their risk of infection-related death was reduced by as much as 60%. The number needed to treat was one infection-related hospital admission prevented for every 48 patients.
That infection angle is genuinely interesting, because it’s not something people typically associate with these drugs. There’s emerging thinking that GLP-1 receptor agonists have anti-inflammatory effects that go beyond weight and glucose control, and infection outcomes are one way that might show up in real-world data. It’s speculative to lean on it too hard, but the observational signal is there.
The whole picture, not just the good bits
The digestive clarity I want to give you is that this is an observational study, and observational means correlation rather than proof.
An editorial that ran alongside the study made exactly this point: the findings strengthen the evidence for the cardiovascular benefits and safety of GLP-1 medications, but the study cannot prove the drugs themselves improved survival. People who stay on tirzepatide and the people who stay on sitagliptin are not interchangeable groups, and claims data can’t fully account for all the differences between them - adherence, lifestyle, other medications, how sick people were at baseline.
There’s also the practical reality that the editorial flags: tirzepatide and the other GLP-1s come with cost, side effects, accessibility and supply challenges, all of which can prevent people from staying on them long enough to see these outcomes. A drug only works if people can actually get it and tolerate it.
What the Research Says
What the study supports:
- In a group of about 53,000 people with excess weight, type 2 diabetes and heart disease, tirzepatide was associated with a one-year heart attack/stroke/death rate of 2.9% versus 4.4% for sitagliptin - roughly a third lower, or one fewer event per 70 patients.
- Tirzepatide was associated with fewer severe bacterial infections, cutting infection-related hospitalisation by about a third and infection-related death by up to 60%.
- The findings align with the broader cardiovascular benefit signal already established for the GLP-1 class.
What it does not support:
- It is not proof that tirzepatide causes the improved outcomes - it’s real-world observational data, not a randomised trial.
- It can’t fully separate the drug’s direct effects from the weight loss, adherence patterns or baseline differences between groups.
- It was in a high-risk population of people with existing heart disease and diabetes, so the numbers shouldn’t be generalised to everyone.
- The infection findings are intriguing but need prospective confirmation before being treated as solid ground.
Why this matters for the research community
For people following the metabolic/diabetes research space, this is another tile in the picture that GLP-1 drugs are cardiovascular drugs as much as weight-loss drugs. We covered the muscle-loss myth versus the evidence and the broader health benefits of the class earlier, and this paper sits in the same lineage.
Tirzepatide is a dual GIP/GLP-1 agonist, and we’ve got a dedicated page on where it sits alongside the other dual and triple agonists in the pipeline. The emerging cardiovascular and infection-benefit data is part of why this class has become such a focus of research interest - the effects keep turning out to be broader than just appetite and glucose.
The honest bottom line is that the cardiovascular story for GLP-1s is now well established across multiple trials and real-world analyses, and this study adds tirzepatide-specific data plus an interesting and less-common infection angle. But the study design means it’s supporting evidence, not the final word. For the DIY research community, the lesson is the same as always: the trials and the real-world data are the foundation, and the grey-market injections of unverified product are a place where none of these rigorous outcomes reliably apply.
Grey Highway is a research-education community. We don’t sell or supply compounds, and we don’t give dosing or medical advice. What we do is read the papers and report what they actually say, benefits and limits both - and this BMJ study is a good example of a finding worth knowing about in full.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources: Harvard Health, “Weight-loss drug may lower risk of heart attacks and infections”, 24 Aug 2026 (health.harvard.edu). The study was published in The BMJ, 8 Aug 2026 issue (claims data May 2022-May 2025, ~53,000 patients). Harvard Health’s summary and the accompanying BMJ editorial were used as the basis for this post.